UK regulators stated today that they have received two reports of potential allergic reactions linked to the COVID-19 vaccine from Pfizer and BioNTech, according to the Associated Press. The individuals who received the vaccine were a part of Britain’s coronavirus vaccination program.
Dr. June Raine, head of the UK’s medical regulatory agency, revealed the news while testifying to a Parliamentary committee on Wednesday. She stated that researchers are still looking into the two alleged reports of allergic reactions, and that clinical trials did not initially reveal these reactions to be a potential problem. Now, regulators are claiming that individuals who have a history of serious allergic reactions should not receive the vaccine.
The news comes after data released on Tuesday showed that out of Pfizer’s 44,000 trial volunteers, there were no participants with a “history of severe adverse reaction associated with a vaccine and/or severe allergic reaction to any component of the study intervention(s).”
Pfizer and BioNTech announced in early November that their Phase III study data showed the vaccine was more than 90% effective in preventing COVID-19 in participants who had not been previously infected. The trial enrolled more than 43,000 subjects at the time, 42% of whom had diverse backgrounds. At the time, no serious safety concerns were reported.